Corrigendum to “Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity” [Mol Metab 78 (2023) 101801]

IF 7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Molecular Metabolism Pub Date : 2024-09-05 DOI:10.1016/j.molmet.2024.102023

Martin Haljeta Friedrichsen , Lars Endahl , Frederik Flindt Kreiner , Ronald Goldwater , Martin Kankam , Søren Toubro , Sune Boris Nygård

引用次数: 0

查看原文本刊更多论文

胰高血糖素/GLP-1 受体合剂 NNC9204-1177 的三项 1 期试验结果：对超重或肥胖成人的减肥效果和安全性》的更正 [Mol Metab 78 (2023) 101801]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

14.50

自引率

2.50%

发文量

219

审稿时长

43 days

期刊介绍： Molecular Metabolism is a leading journal dedicated to sharing groundbreaking discoveries in the field of energy homeostasis and the underlying factors of metabolic disorders. These disorders include obesity, diabetes, cardiovascular disease, and cancer. Our journal focuses on publishing research driven by hypotheses and conducted to the highest standards, aiming to provide a mechanistic understanding of energy homeostasis-related behavior, physiology, and dysfunction. We promote interdisciplinary science, covering a broad range of approaches from molecules to humans throughout the lifespan. Our goal is to contribute to transformative research in metabolism, which has the potential to revolutionize the field. By enabling progress in the prognosis, prevention, and ultimately the cure of metabolic disorders and their long-term complications, our journal seeks to better the future of health and well-being.